What Cramer's Buying Now: Stephanie Link, director of research for Jim Cramer's Action Alerts Plus Portfolio, details the stocks her team is buying right now.
Click here to watch the video.

The Week's Shocker Stock: Stephanie Link, director of research for the Action Alerts PLUS Portfolio, unveils the shocker stock of the week and explains why it's safe even without a dividend.
Click here to watch the video.

Don’t forget Celegene [CELG], adds Guy Adami. They have no debt and a great balance sheet.

Cramer: Obama's Win Gives Us Two Markets: In the short term I'm bullish; in long term I'm bearish, says Jim Cramer.
Click here to watch the video.

In the pharma space I also like Celegene, adds Pete Najarian. Any company that’s acquiring or developing drugs should be promising.

I’d keep an eye on Celgene [CELG] and CME [CME], adds Joe Terranova. They look like they’re oversold to me.

Najarian told viewers to look at Celgene (CELG) which he says is too cheap at $55.
Final Trade

Celgene (CELG) was upgraded from Neutral to Outperform at Cowen. Valuation call, as the stock is not fully pricing in the company's expected growth over the next few years.

There are two major camps right now. One group is betting against the plan and is buying high-growth stocks with no economic exposure like Gilead (GILD) and Celgene (CELG) or the Procters (PG) of the world.

But how about the stocks on the Nasdaq? The Nazz futures are indicating down huge. Does that make sense? Just because it is happening, does that make sense? Symantec (SYMC), positive article this weekend -- a buy? If the futures take it down, yes. Amgen (AMGN) with new data coming up? Yes. Celgene (CELG), which wouldn't come down last week? Yes.

eh

Don't get me started on the disappointment.

lost money on it

everytime i buy it, it goes down

I held it to long and road it to the bottom

It just keeps going down

Have owned stock for 7 months and it hasn't moved or lived up to the expected high growth. IBD Rank B+.

One-trick pony: their new drugs are for the treatment of very few patients with rare diseases; no therapies for broader usage

P/E (ttm) 321.78. This does not send up a red flag ???Astronomical PE. Buy low, sell high -- you're a genius; buy high, sell low -- you're a chump. Not only that, the emperor pays no dividend.